Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NefIgArd: Efficacy and Safety of Nefecon in Primary IgA Nephropathy
2017-004902-16Phase 3Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Nefecon with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint (Part A). Started Feb 2018; status: completed.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2017-004902-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004902-16.